EMA Recommends Approval of First RSV Vaccine for Older Adults
The EMA has issued a positive opinion for GSK's Arexvy, the first RSV vaccine for adults aged 60 and over. This marks a significant step in protecting older populations from RSV-related respiratory illness. Healthcare professionals can look forward to expanded preventive options pending final approval.
- Published date: 09-06-2026 10:04 AM
The European Medicines Agency (EMA) has recommended the approval of the first respiratory syncytial virus (RSV) vaccine for adults aged 60 years and older. The vaccine, developed by GSK and marketed as Arexvy, is designed to help protect older adults from lower respiratory tract disease caused by RSV infection.
RSV is a common respiratory virus that can cause serious illness in older adults and those with underlying health conditions. The EMA's positive opinion follows a comprehensive review of clinical trial data demonstrating the vaccine's efficacy and safety profile in the target population.
The European Commission will now consider the EMA's recommendation, and a final decision on marketing authorization is expected in the coming months. If approved, Arexvy will be the first RSV vaccine available for older adults in the European Union, potentially reducing the burden of RSV-related hospitalizations and complications.
The EMA has issued a positive opinion for GSK's Arexvy, the first RSV vaccine for adults aged 60 and over. This marks a significant step in protecting older populations from RSV-related respiratory illness. Healthcare professionals can look forward to expanded preventive options pending final approval.